Role of Inflammation and Infection in Vascular Disease

References

• Pearson T., Mensah G., Alexander R. W., Anderson J. L., Cannon III R. O., Criqui M., Fadl Y., Fortmann S., Hong Y., Myers G. L., Rifai N., Smith S., Taubert K., Tracy R., Vinicor F. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003, 107: 499–511.
   Google Scholar
• Danesh J., Whincup P., Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ, 2000, 321: 199–204.
   Google Scholar
• Ridker P. M., Cushman M., Tampfer J. S., Russell P. T., Hennekens e. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. N Engl J Med, 1997, 336: 973–9.
   Google Scholar
• Ridker P. M., Glynn J. G., Hennekens e. H. C-reactive protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction. Circulation, 1998, 97: 2007–11.
   Google Scholar
• Ridker P. M., Buring J. E., Shih J., Matias M., Hennekens e. H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 1998, 98: 731–3.
   Google Scholar
• Brevetti G., Piscione F., Silvestro A., Galasso G., Di Donato A., Oliva G., Scopacasa F., Chiariello M. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost, 2003, 89: 1058–63.
   Google Scholar
• Vainas T., Lubbers T., Stassen F. R., Herngreen S. B., van Dieijen-Visser M. P., Bruggeman e. A., Kitslaar P. J., Schurink G. W. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneuris-mal tissue. Circulation, 2003, 107: 1103–5.
   Google Scholar
• Novo S., Basili S., Tantillo R., Falco A., Davì V., Novo G., Corrado E., Davì G. Soluble CD40L and cardiovascular risk in asymptomatic carotid plaque. Stroke, 2005, 36: 673–5.
   Google Scholar
• Maresca G., Di Blasio A., Marchioli R., Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol, 1999, 19: 1368–77.
   Google Scholar
• Abrignani M. G., Novo G., Di Girolamo A., Caruso R., Tantillo R., Braschi A., Braschi G. B., Strano A., Novo S. increased plasmatic levels of fibrinogen in acute and chronic ischemic coronary syndromes. Cardiologia, 1999, 44: 1047–52.
   Google Scholar
• Coppola G., Rizzo M., Abrignani M. G., Corrado E., Di Girolamo A., Braschi G. B., Novo S. Fibrinogen as predictor of mortality after acute myocardial infarction: a 42-months follow-up study. It Heart J, 2005, 6: 315–22.
   Google Scholar
• Coppola G., Corrado E., Muratori I., Tantillo R., Vitale G., Lo Coco L., Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol, 2005, e-publication.
   Google Scholar
• Ridker P. M., Rifai N., Pfeffer M. A., Sacks F. M., Moye L. A., Goldman S., Flaker G. e., Braunwald E. Inflammation, Pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98: 839–44.
   Google Scholar
• Albert M. A., Danielson E., Rifai N., Ridker P. M., for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001, 286: 64–70.
   Google Scholar
• Ridker P. M., Rifai N., Clearfield M., Downs J. R., Weis S. E., Miles J. S., Gotto A. M. Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 2001, 344: 1959–65.
   Google Scholar
• Kinlay S., Schwartz G., Olsson A. G., Rifai N., Leslie S., Sasiela W., Szarek M., Libby P., Ganz P., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIR-ACL) Study Investigators High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute CoronarySyndromes in the MIRACL Study. Circulation, 2003, 108: 1560–6.
   Google Scholar
• Nissen S., Tuzcu E. M., Schoenhagen, Brown G., Ganz P., Vogel R. A., Crowe T., Howard G., Cooper e., Brodie B., Grines e. L., DeMaria A., for the REVERSAL Investigators. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA, 2004, 291: 1071–80.
   Google Scholar
• Ridker P. M., Morrow D., Rose L., Rifai N., Cannon e. P., Braunwald E. Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol < 70 mg/dl and C-Reactive Protein < 2 mg/l. An Analysis of the PROVE-IT TIMI-22 Trial. J Am Coll Cardiol 2005, 45: 1644–8.
   Google Scholar
• de Lemos J. A., Blazing M. A., Wiviott S., Lewis E., Fox K. A., White e., Rouleau J., Pedersen T., Gardner L., Mukherjee R., Ramsey K., Palmisano J., Bilheimer D., Pfeffer M., Califf R., Braunwald E., for the A to Z Investigators. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients with Acute Coronary Syndromes Phase Z of the A to Z Trial. JAMA, 2004, 292: 1307–16.
   Google Scholar
• Jialal I., Stein D., Balis D., Grundy S. M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001, 103: 1933–5.
   Google Scholar
• Horne B. D., Muhlestein J. B., Carlquist J. F., Bair T. L., Madsen T. E., Hart N. I., Anderson J. L. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angio-graphically severe coronary artery disease. J Am Coll Cardiol, 2000, 36: 1774–80.
   Google Scholar
• DE Maat M. P. M., Knipscheer H. e., Kastelein J. J. P., Kluft e. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost, 1997, 77: 75–9.
   Google Scholar
• Cortellaro M., Cofrancesco E., Boschetti e., Cortellaro F., Mancini M., Mariani M., Paoletti R., on behalf of the FACT study centers. Effects of fluvastatin and Bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidemia (FACT study). Thromb Haemost, 2000, 83: 549–53.
   Google Scholar
• Heiss G., Sharrett A. R., Barnes R., Chambless L. E., Szklo M., Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991, 134: 250–6.
   Google Scholar
• Zhou Y. F., Leon M. B., Waclawiw M. A., Popma J. J., Yu Z. X., Finkel T., Epstein S. E. Association between prior cytomegalo-virus infection and the risk of restenosis after coronary atherecto-my. NEngl J Med, 1996, 335: 624–30.
   Google Scholar
• Everett J. P., Hershberger R. E., Norman D. J., Chou S., Ratkovec R. M., Cobanoglu A., Ott G. Y., Hosenpud J. D. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant, 1992, 11: S133–S137.
   Google Scholar
• Biasucci L. M., Liuzzo G., Cervo A., Petrucca A., Piro M., Angiolillo D. J., Crea F., Cassone A., Maseri A. Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes. Circulation, 2003, 107: 3015–17.
   Google Scholar
• Huittinen T., Leinonen M., Tekanen L., Mänttäri M., ViRKKUNEN H., Pitkänen T., Wahlström E., Palosuo T., Manninen V., Saikku P. Autoimmunity to Human Heat Shock Protein 60, Chlamydia pneumoniae Infection, and Inflammation in Predicting Coronary Risk. Arterioscler Thromb Vasc Biol, 2002, 22: 431–7.
   Google Scholar
• Wick G., Perchinka H., Xu Q. Autoimmunity and atherosclerosis. Am Heart J, 1999, 138: 444–9.
   Google Scholar
• Ridker P. M., Danesh J., Youngman L., Collins R., Stampfer M. J., Peto R., Hennekens C. H. A Prospective Study of Helicobacter pylori Seropositivity and the Risk for Future Myocardial Infarction among Socioeconomically Similar U.S. Men. Ann Intern Med, 2001, 135: 184–8.
   Google Scholar
• Aceti A., Are R., Sabino G., Fenu L., Pasquazzi C., Quaranta G., Zechini B., Terrosu P. Helicobacter pylori active infection in patients with acute coronary heart disease. J Infect, 2004, 49: 8–12.
   Google Scholar
• Hara K., Morita Y., Kamihata H., Iwasaka T., Takahashi H. Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. Clin Chim Acta, 2001, 313: 87–94.
   Google Scholar
• Saikku P., Leinonen M., Tekanen L., Linnanmaki E., Ekman M. R., Manninen V., Mänttäri M., Frick M. H., Huttunen J. K. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med, 1992, 116: 273–8.
   Google Scholar
• Tarnacka B., Gromadzka G., Czlonkowska A. Increased Circulating Immune Complexes in Acute Stroke: The Triggering Role of Chlamydia pneumoniae and Cytomegalovirus. Stroke, 2002, 33: 936–40.
   Google Scholar
• Johnson S. P., Overvad K., Ostergaard L., Tjonneland A., Husted S. E., Sorensen H. T. Chlamydia pneumoniae seropositiv-ity and risk of ischemic stroke: a nested case-control study. Eur J Epidemiol, 2005, 20: 59–65.
   Google Scholar
• Cremonini F., Gabrielli M., Gasbarrini G., Pola P., Gasbarrini A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis, 2004, 173: 253–9.
   Google Scholar
• Zhu J., Quyyumi A. A., Norman J. E., Csako G. A., Shearer G. M., Grayston J. T., Epstein S. E. Total pathogen burden contributes incrementally to coronary artery disease risk and to C-reactive protein levels. Circulation, 1998, 98 (suppl. I): I-142. Abstract.
   Google Scholar
• Corrado E., Tantillo R., Muratori I., Evola G., Vitale G., Rizzo M., Mansueto S., Strano A., Novo S. Infection and inflammation influence the outcome of patients with asymptomatic carotid lesions. Int Angiol, 2004, 23 (Suppl. 1 to issue n° 1), pp. 168. Abstract.
   Google Scholar
• Muratori I., Vitale G., Evola S., Evola G., Tantillo R., Mocciaro C., Noto D., Di Giovanni S., Di Simone E., Giglia S., Mansueto S., Novo S. Infection from Helicobacter Pylori, Chlamydia Pneumoniae, Cytomegalovirus, levels of C-reactive protein and fibrinogen in patients with acute and chronic coronary ischemia in comparison with control subjects. Min Cardioangiol, 2001, 49 (Suppl. 1/6): 192–4.
   Google Scholar
• Anderson J. L., Muhlestein J. B., Carlquist J., Allen A., Trehan S., Nielson C. et al. Randomized secondary prevention trial of Azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation, 1999, 99: 1540–7.
   Google Scholar
• Grayston J. T. Secondary prevention antibiotic treatment trials for coronary artery disease. Circulation, 2000, 102: 1742–3.
   Google Scholar
• Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. Randomised trial of Roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet, 1997, 350: 404–7.
   Google Scholar
• Sinisalo J., Mattila K., Valtonen V., Anttonen O., Juvonen J., Melin J. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation, 2002, 105: 1555–60.
   Google Scholar
• Neumann F., Kastrati A., Miethke T., Pogatsa-Murray G., Mehilli J., Valina C. Treatment of Chlamydia pneumoniae infection with Roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, doubleblind, placebo-controlled trial. Lancet, 2001, 357: 2085–9.
   Google Scholar